Abcuro is developing first-in-class immunotherapies for the treatment of autoimmune diseases and cancer through precise modulation of highly cytotoxic T and NK cells.
Affinia is developing next-generation AAV gene therapies for rare and non-rare diseases.
Claris is a pre-clinical stage company focused on novel therapeutics for front of the eye diseases.
FireCyte is developing novel treatment strategies for progressive neurodegenerative diseases of the eye.
Co-founded by clinicians from McLean Hospital, InStride offers technology-enhanced mental health treatment for adolescents.
Mediar is developing antibody-based therapeutics to halt fibrosis in a variety of organ systems, including lung, liver, kidney, and skin.
Nocion is developing novel small molecule charged sodium channel blockers, “nocions,” that selectively affect actively firing nociceptors to treat neuroinflammatory indications.
Photys is developing a new class of bifunctional drugs for phosphorylation of kinases to treat cancer.
Pykus is developing a novel intraocular polymer to replace the vitreous humor following retinal surgery.
QurAlis is developing precision medicines for amyotrophic lateral sclerosis (ALS) and other neurologic diseases.
Rippl is pioneering a new care model to expand access to mental health care for seniors, their families, and caregivers.
Rome is unlocking the hidden genome by targeting the RNA "repeatome" to treat autoimmune disease and cancer.
SwanBio is advancing AAV-based gene therapies for the treatment of neurological diseases, including adrenomyeloneuropathy.
Stratus is pioneering full hematopoietic system renewal through its novel platform, Stratus Prime™, and lead product candidate, ST-101.
Tuesday Health is a value-based, supportive care organization that is revolutionizing the approach to serious illness and end-of-life care.
Violet is leveraging first-in-class platforms to identify, map and mine the cellular connectome at scale.
Walden BioSciences is transforming the treatment of kidney disease by restoring or preserving podocyte function.
ZielBio is developing targeted therapies against novel targets for cancer.
Since inception, Mass General Brigham Ventures has realized 20 exits, including eight initial public offerings and 12 mergers and acquisitions. These portfolio companies are spearheading novel approaches to diagnose, prevent and treat a wide range of medical conditions.
Adheron Therapeutics
Acquired by Roche (ADR: RHHBY)
Oct. 2015
Monoclonal antibody (mAb) therapy for inflammatory diseases including rheumatoid arthritis.
Amolyt Pharma
Acquired by AstraZeneca (NASDAQ: AZN)
Mar. 2024
Therapeutic peptides for rare endocrine and metabolic diseases.
Annovation BioPharma
Acquired by The Medicines Company (NASDAQ: MDCO)
Jan. 2015
Novel precision anesthetics.
CoStim Pharmaceuticals
Acquired by Novartis (NYSE: NVS)
Feb. 2014
Next-generation immuno-oncology drugs based on T-cell costimulatory targets.
LifeImage
Acquired by Intelerad Medical Systems
Sep. 2022
Digital diagnostic image sharing platform.
Lysosomal Therapeutics
Acquired by Bial Biotech
Oct. 2020
Novel personalized medicine platform to treat neurodegenerative diseases, targeting the mutant GBA1 gene.
QPID Health
Acquired by eviCore Healthcare
Feb. 2016
EHR analytics software – extracting insight from information.
Scorpion
Acquired by Eli Lilly (NTSE: LLY)
Jan. 2025
Next-generation precision oncology company.
SeQure
Acquired by MaxCyte (NASDAQ: MXCT)
Jan. 2025
Best-in-class technology to identify and manage the risks of off-target gene-editing agents.
Syntimmune
Acquired by Alexion (NASDAQ: ALXN)
Nov. 2018
Advances the fight against autoimmune disease.
Tilos Therapeutics
Acquired by Merck (NYSE: MRK)
June 2019
Anti-LAP antibodies: transforming the tumor microenvironment to treat cancer.
IPO June 2020 (NASDAQ: AKUS); acquired by Lilly (NYSE: LLY) Dec. 2022
Precision genetic medicine company focused on inner ear disorders, including sensorineural hearing loss.
IPO Dec. 2017 (NASDAQ: DNLI)
Defeating neurodegenerative diseases.
IPO Feb. 2016 (NASDAQ: EDIT)
Unlocking the power and potential of CRISPR genome editing technology.
IPO April 2020 (NASDAQ: KROS)
Novel treatments for patients suffering from hematologic and musculoskeletal disorders.
IPO June 2018 (NASDAQ: MGTA)
Revolutionizing stem cell transplant as the new treatment paradigm for immunologic and blood-based diseases.
IPO Nov. 2017 (NASDAQ: SPRO)
Anti-infectives targeting Gram-negative bacteria.
IPO June 2018 (NASDAQ:TBIO), acquired by Sanofi (NASDAQ: SNY) Sep. 2021
Developing messenger RNA (mRNA) therapies.
IPO June 2021 (NASDAQ:VERV)
Pioneering single-course gene editing medicines to treat cardiovascular disease.